Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given an average rating of "Buy" by the fifteen research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $43.93.

Several research firms have recently commented on DYN. Guggenheim reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, June 18th. Robert W. Baird reduced their target price on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research note on Wednesday, June 18th. Raymond James Financial initiated coverage on shares of Dyne Therapeutics in a research note on Wednesday, June 11th. They set an "outperform" rating and a $37.00 target price for the company. HC Wainwright reduced their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price for the company.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its holdings in shares of Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock worth $5,532,000 after purchasing an additional 698 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in shares of Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 5.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock worth $237,000 after purchasing an additional 1,115 shares in the last quarter. E Fund Management Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after purchasing an additional 1,249 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock worth $183,000 after purchasing an additional 1,481 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Trading Down 4.3%

NASDAQ:DYN opened at $10.32 on Monday. The firm has a market capitalization of $1.17 billion, a PE ratio of -2.87 and a beta of 1.17. The stock has a 50 day moving average of $11.60 and a 200-day moving average of $14.39. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.